145 related articles for article (PubMed ID: 27248664)
1. BO-1055, a novel DNA cross-linking agent with remarkable low myelotoxicity shows potent activity in sarcoma models.
Ambati SR; Shieh JH; Pera B; Lopes EC; Chaudhry A; Wong EW; Saxena A; Su TL; Moore MA
Oncotarget; 2016 Jul; 7(28):43062-43075. PubMed ID: 27248664
[TBL] [Abstract][Full Text] [Related]
2. Repairing of N-mustard derivative BO-1055 induced DNA damage requires NER, HR, and MGMT-dependent DNA repair mechanisms.
Kuo CY; Chou WC; Wu CC; Wong TS; Kakadiya R; Lee TC; Su TL; Wang HC
Oncotarget; 2015 Sep; 6(28):25770-83. PubMed ID: 26208482
[TBL] [Abstract][Full Text] [Related]
3. PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models.
Pignochino Y; Capozzi F; D'Ambrosio L; Dell'Aglio C; Basiricò M; Canta M; Lorenzato A; Vignolo Lutati F; Aliberti S; Palesandro E; Boccone P; Galizia D; Miano S; Chiabotto G; Napione L; Gammaitoni L; Sangiolo D; Benassi MS; Pasini B; Chiorino G; Aglietta M; Grignani G
Mol Cancer; 2017 Apr; 16(1):86. PubMed ID: 28454547
[TBL] [Abstract][Full Text] [Related]
4. Enhancement of radiosensitivity in human glioblastoma cells by the DNA N-mustard alkylating agent BO-1051 through augmented and sustained DNA damage response.
Chu PM; Chiou SH; Su TL; Lee YJ; Chen LH; Chen YW; Yen SH; Chen MT; Chen MH; Shih YH; Tu PH; Ma HI
Radiat Oncol; 2011 Jan; 6():7. PubMed ID: 21244709
[TBL] [Abstract][Full Text] [Related]
5. A combined DNA-affinic molecule and N-mustard alkylating agent has an anti-cancer effect and induces autophagy in oral cancer cells.
Lo WL; Chu PY; Lee TH; Su TL; Chien Y; Chen YW; Huang PI; Tseng LM; Tu PH; Kao SY; Lo JF
Int J Mol Sci; 2012; 13(3):3277-3290. PubMed ID: 22489152
[TBL] [Abstract][Full Text] [Related]
6. STA-8666, a novel HSP90 inhibitor/SN-38 drug conjugate, causes complete tumor regression in preclinical mouse models of pediatric sarcoma.
Heske CM; Mendoza A; Edessa LD; Baumgart JT; Lee S; Trepel J; Proia DA; Neckers L; Helman LJ
Oncotarget; 2016 Oct; 7(40):65540-65552. PubMed ID: 27608846
[TBL] [Abstract][Full Text] [Related]
7. The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin.
Ordóñez JL; Amaral AT; Carcaboso AM; Herrero-Martín D; del Carmen García-Macías M; Sevillano V; Alonso D; Pascual-Pasto G; San-Segundo L; Vila-Ubach M; Rodrigues T; Fraile S; Teodosio C; Mayo-Iscar A; Aracil M; Galmarini CM; Tirado OM; Mora J; de Álava E
Oncotarget; 2015 Aug; 6(22):18875-90. PubMed ID: 26056084
[TBL] [Abstract][Full Text] [Related]
8. Integrated Molecular Characterization of Patient-Derived Models Reveals Therapeutic Strategies for Treating CIC-DUX4 Sarcoma.
Carrabotta M; Laginestra MA; Durante G; Mancarella C; Landuzzi L; Parra A; Ruzzi F; Toracchio L; De Feo A; Giusti V; Pasello M; Righi A; Lollini PL; Palmerini E; Donati DM; Manara MC; Scotlandi K
Cancer Res; 2022 Feb; 82(4):708-720. PubMed ID: 34903601
[TBL] [Abstract][Full Text] [Related]
9. The novel DNA alkylating agent BO-1090 suppresses the growth of human oral cavity cancer in xenografted and orthotopic mouse models.
Sanjiv K; Su TL; Suman S; Kakadiya R; Lai TC; Wang HY; Hsiao M; Lee TC
Int J Cancer; 2012 Mar; 130(6):1440-50. PubMed ID: 21500194
[TBL] [Abstract][Full Text] [Related]
10. Trabectedin and Campthotecin Synergistically Eliminate Cancer Stem Cells in Cell-of-Origin Sarcoma Models.
Martinez-Cruzado L; Tornin J; Rodriguez A; Santos L; Allonca E; Fernandez-Garcia MT; Astudillo A; Garcia-Pedrero JM; Rodriguez R
Neoplasia; 2017 Jun; 19(6):460-470. PubMed ID: 28494349
[TBL] [Abstract][Full Text] [Related]
11. Perifosine and sorafenib combination induces mitochondrial cell death and antitumor effects in NOD/SCID mice with Hodgkin lymphoma cell line xenografts.
Locatelli SL; Giacomini A; Guidetti A; Cleris L; Mortarini R; Anichini A; Gianni AM; Carlo-Stella C
Leukemia; 2013 Aug; 27(8):1677-87. PubMed ID: 23360848
[TBL] [Abstract][Full Text] [Related]
12. The histone deacetylase inhibitor PXD101 increases the efficacy of irinotecan in in vitro and in vivo colon cancer models.
Na YS; Jung KA; Kim SM; Hong YS; Ryu MH; Jang SJ; Moon DH; Cho DH; Kim JC; Lee JS; Kim TW
Cancer Chemother Pharmacol; 2011 Aug; 68(2):389-98. PubMed ID: 21046105
[TBL] [Abstract][Full Text] [Related]
13. Autophagy inhibition enhances apoptosis triggered by BO-1051, an N-mustard derivative, and involves the ATM signaling pathway.
Chen LH; Loong CC; Su TL; Lee YJ; Chu PM; Tsai ML; Tsai PH; Tu PH; Chi CW; Lee HC; Chiou SH
Biochem Pharmacol; 2011 Mar; 81(5):594-605. PubMed ID: 21184746
[TBL] [Abstract][Full Text] [Related]
14. Irinophore C™, a lipid nanoparticulate formulation of irinotecan, improves vascular function, increases the delivery of sequentially administered 5-FU in HT-29 tumors, and controls tumor growth in patient derived xenografts of colon cancer.
Neijzen R; Wong MQ; Gill N; Wang H; Karim T; Anantha M; Strutt D; Waterhouse D; Bally MB; Tai IT; Ng SS; Yapp DT
J Control Release; 2015 Feb; 199():72-83. PubMed ID: 25497312
[TBL] [Abstract][Full Text] [Related]
15. An aza-macrocycle containing maltolic side-arms (maltonis) as potential drug against human pediatric sarcomas.
Guerzoni C; Amatori S; Giorgi L; Manara MC; Landuzzi L; Lollini PL; Tassoni A; Balducci M; Manfrini M; Pratelli L; Serra M; Picci P; Magnani M; Fusi V; Fanelli M; Scotlandi K
BMC Cancer; 2014 Feb; 14():137. PubMed ID: 24575739
[TBL] [Abstract][Full Text] [Related]
16. Multimodal targeting of tumor vasculature and cancer stem-like cells in sarcomas with VEGF-A inhibition, HIF-1α inhibition, and hypoxia-activated chemotherapy.
Yoon C; Chang KK; Lee JH; Tap WD; Hart CP; Simon MC; Yoon SS
Oncotarget; 2016 Jul; 7(28):42844-42858. PubMed ID: 27374091
[TBL] [Abstract][Full Text] [Related]
17. Arsenic trioxide induces programmed cell death through stimulation of ER stress and inhibition of the ubiquitin-proteasome system in human sarcoma cells.
Chiu HW; Tseng YC; Hsu YH; Lin YF; Foo NP; Guo HR; Wang YJ
Cancer Lett; 2015 Jan; 356(2 Pt B):762-72. PubMed ID: 25449439
[TBL] [Abstract][Full Text] [Related]
18. Preclinical efficacy of the bioreductive alkylating agent RH1 against paediatric tumours.
Hussein D; Holt SV; Brookes KE; Klymenko T; Adamski JK; Hogg A; Estlin EJ; Ward T; Dive C; Makin GW
Br J Cancer; 2009 Jul; 101(1):55-63. PubMed ID: 19491903
[TBL] [Abstract][Full Text] [Related]
19. Mechanism of action and preclinical antitumor activity of the novel hypoxia-activated DNA cross-linking agent PR-104.
Patterson AV; Ferry DM; Edmunds SJ; Gu Y; Singleton RS; Patel K; Pullen SM; Hicks KO; Syddall SP; Atwell GJ; Yang S; Denny WA; Wilson WR
Clin Cancer Res; 2007 Jul; 13(13):3922-32. PubMed ID: 17606726
[TBL] [Abstract][Full Text] [Related]
20. Preclinical studies of treosulfan demonstrate potent activity in Ewing's sarcoma.
Werner S; Mendoza A; Hilger RA; Erlacher M; Reichardt W; Lissat A; Konanz C; Uhl M; Niemeyer CM; Khanna C; Kontny U
Cancer Chemother Pharmacol; 2008 Jun; 62(1):19-31. PubMed ID: 17823799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]